QNRX | Quoin Pharmaceuticals, Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2153 - 0.2480
52 Week Range	0.2153 - 1.5700
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	287,529
Average Volume	5,551,696
Shares Outstanding	8,948,164
Market Cap	2,003,494
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-08-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.12
Forward P/E Ratio	N/A
EPS	-1.91
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	QNRX

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

QNRX's peers: ADTX, ALLR, APVO, ATHE, NTRB, CMMB, COCP, ABVC, EDSA, CELZ, ENSC, EQ, EVAX, GTBP, GOVX, HOTH, IKT, INDP, INM, KPRX, KTTA, KZIA, LGVN, LIXT, NLSP, NNVC, NRSN, NRXP, PSTV, PTN, BWV, PXMD, REVB, HILS, VRAX, NRBO, KRBP, BDRX, UNCY, CDIO, RNXT, SABS, SIDU, SPRC, TENX, TLSA, TTNP, VRPX, VS, VTGN, VTVT, XRTX, OKYO, SNTI, IMNN, ICU, CMND, DOMH, CVKD

*Chart delayed

Analyzing fundamentals for QNRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see QNRX Fundamentals page.

Watching at QNRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on QNRX Technicals page.